Download

Download Full Text (113 KB)

Description

This commentary analyzes how biotechnology provisions in the FY 2026 National Defense Authorization Act (NDAA) reflect emerging opportunities and challenges for U.S. national security. It explains that key investments in bioindustrial capacity, synthetic biology, bioinformatics, and related research signal a strategic shift toward integrating biological technologies into defense planning. While these advancements can strengthen biodefense, medical readiness, and operational resilience, they also raise policy, ethical, and governance questions about prioritization, oversight, and risk management. Dr. Giordano offers practical recommendations, including the need for enhanced workforce education, robust interdisciplinary coordination, and international collaboration to ensure responsible innovation. Aligning biotechnology investment with strategic deterrence will be critical for maintaining competitive advantage amid rapid global technological change.

Document Type

Article

Topic(s)

Emerging Science and Technologies, Defense Policy, National Security

Region(s)

United States

Publication Date

12-17-2025

Keywords

biotechnology policy, FY 2026 NDAA, national defense authorization, synthetic biology, bioindustrial base, biodefense, bioinformatics, strategic investment, defense innovation, national security technology, ethical governance, workforce education, international collaboration

Biotechnology in the FY 2026 NDAA: Strategic Implications — and Recommendations — for Joint Force Readiness

Share

COinS